Akoya Biosciences Inc Stock News

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels

CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya's IVD assays currently in development. T...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Akoya stoc...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya common stock is fair to Akoya shareholders. Halper Sadeh encourages Akoya shareholders to click here to learn more about their legal rights and options or ...

BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the f...

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease Akoya expands clinical test menu,...

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro ...